Compare ING Groep NV (ING) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Vertex Pharmaceuticals Incorporated — how do they compare? ING Groep NV trades at $33.26 (market cap $93.76B), while Vertex Pharmaceuticals Incorporated trades at $510.9 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and ING Groep NV pays a 3.95% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ING | VRTX | |
|---|---|---|
Market Cap | $93.76B | $127.55B |
Volume | 4,620,220 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $37.27 | $557.96 |
52-Week Low | $23.66 | $407.37 |
Typical Hold Time | 93 Days | 120 Days |
Enterprise Value | $236.48B | $121.68B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.28, down 1.89% today, with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains a 28.34% net income margin, and analysts show strong support with 11 buy ratings versus no sell ratings. Recent news highlights management's raised ROE target above 16% for 2027 and strategic focus on organic growth.
The investment case balances solid profitability and analyst optimism against technical weakness and cash flow challenges. Upside potential exists from earnings momentum and strategic initiatives, while risks include persistent negative operating cash flows and regulatory scrutiny in international markets.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
